Click Here for 5% Off Your First Aladdin Purchase!

CTAP - ≥95%, high purity , CAS No.103429-32-9, Antagonist of δ receptor;Antagonist of μ receptor

  • Moligand™
  • ≥95%
Item Number
C118803
Grouped product items
SKUSizeAvailabilityPrice Qty
C118803-1mg
1mg
In stock
$127.90
C118803-5mg
5mg
In stock
$572.90
C118803-25mg
25mg
In stock
$2,577.90

Potent, selective μ opioid antagonist

Basic Description

SynonymsCTAP|103429-32-9|CHEMBL1795717|TCTAP|(4R,7S,10S,13R,16S,19R)-N-[(2S,3R)-1-Amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-
Specifications & PurityMoligand™, ≥95%
Biochemical and Physiological MechanismsSelective μ-opioid receptor antagonist.Potent and selective μ opioid receptor antagonist (1200-fold more selective vs . δ receptor). Blood-brain barrier permeable and active in vivo . Antagonizes antinociceptive effect.CTAP is a polypeptide antagonist pre
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeANTAGONIST
Mechanism of actionAntagonist of δ receptor;Antagonist of μ receptor
NoteThis product is supplied in one (or more) pack size which is freeze dried. Therefore the contents may not be readily visible, as they can coat the bottom or walls of the vial. Please see our FAQs and information page for more details on handling. Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one week. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description

Amino Acid Sequence Phe-Cys-Tyr-Trp-Arg-Thr-Pen-Thr-NH2

Associated Targets

SSTR1 Tclin Somatostatin receptor type 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRD1 Tclin Delta-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRM1 Tclin Mu-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name (4R,7S,10S,13R,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
INCHI InChI=1S/C51H69N13O11S2/c1-26(65)39(42(53)68)62-49(75)41-51(3,4)77-76-25-38(61-43(69)33(52)21-28-11-6-5-7-12-28)47(73)59-36(22-29-16-18-31(67)19-17-29)45(71)60-37(23-30-24-57-34-14-9-8-13-32(30)34)46(72)58-35(15-10-20-56-50(54)55)44(70)63-40(27(2)66)48(74)64-41/h5-9,11-14,16-19,24,26-27,33,35-41,57,65-67H,10,15,20-23,25,52H2,1-4H3,(H2,53,68)(H,58,72)(H,59,73)(H,60,71)(H,61,69)(H,62,75)(H,63,70)(H,64,74)(H4,54,55,56)/t26-,27-,33-,35+,36+,37-,38+,39+,40+,41-/m1/s1
InChi Key OFMQLVRLOGHAJI-FGHAYEPSSA-N
Canonical SMILES CC(C1C(=O)NC(C(SSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)(C)C)C(=O)NC(C(C)O)C(=O)N)O
Isomeric SMILES C[C@H]([C@H]1C(=O)N[C@@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)N)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
WGK Germany 3
PubChem CID 10418702
Molecular Weight 1104.3

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

5 results found

Lot NumberCertificate TypeDateItem
E1527197Certificate of AnalysisJan 06, 2023 C118803
J2229167Certificate of AnalysisSep 23, 2022 C118803
J2229168Certificate of AnalysisSep 23, 2022 C118803
J2229169Certificate of AnalysisSep 23, 2022 C118803
B2225353Certificate of AnalysisDec 23, 2021 C118803

Safety and Hazards(GHS)

WGK Germany 3

Related Documents

References

1. Furukawa A et al..  (2018)  Endothelin Signaling Contributes to Modulation of Nociception in Early-stage Tongue Cancer in Rats..  Anesthesiology,  128  (6): (1207-1219).  [PMID:29461271]

Solution Calculators